Cardior Pharmaceuticals

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing RNA-based therapeutics to treat heart disease. They are pioneers in the field, leveraging their expertise in RNA biology to create innovative therapies that address the root causes of cardiac dysfunction. Cardior's lead candidate, CDR132L, is a novel oligonucleotide-based inhibitor of miR-132, designed to reverse adverse cardiac remodeling after myocardial infarction. CDR132L has shown promising results in clinical trials, demonstrating its potential to improve heart function and quality of life for heart failure patients.

The company's mission is to bring transformative treatments to millions of patients worldwide. Cardior is committed to maintaining high ethical and compliance standards, collaborating with partners, and advancing their therapeutic pipeline to meet the unmet needs of patients with heart disease. They believe in pushing the boundaries of heart disease treatment and making a lasting impact on the lives of those affected.

Cardior Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to pioneering the discovery and development of RNA-based therapeutics for the treatment of cardiac diseases. They leverage their deep expertise in RNA biology to address the root causes of heart disease, aiming to create transformative therapies and diagnostics that will prevent, repair, and reverse cardiac dysfunctions. Their mission is to bring innovative treatments to patients worldwide, ultimately making a lasting impact on the lives of millions affected by heart disease.

Cardior Pharmaceuticals promotes a culture of innovation and collaboration, focused on making a lasting impact on the lives of patients with heart disease. Their commitment to pushing boundaries and exploring new frontiers in heart disease treatment is evident in their pioneering work with non-coding RNA-based therapeutics. The company values scientific excellence and entrepreneurial spirit, attracting and supporting a diverse and talented team.